Market Overview
According to fortune business insights, the global molecular modelling market is witnessing significant growth, driven by the rising need for drug discovery and development to combat the increasing incidence of chronic diseases. The market growth is further bolstered by a shift toward personalized medicine and continuous technological advancements. In 2023, North America accounted for the largest share of the global molecular modelling market. While specific market size figures are not provided, biopharma companies spent USD 247 billion on clinical R&D in 2023, a figure projected to rise to USD 285 billion by 2028, indicating a strong underlying demand for molecular modelling tools and services.
This analysis shows that increasing R&D activities and advancements in computational power are accelerating the adoption of molecular modelling. For example, the Journal of Informatics in Medicine Unlocked noted in 2022 that computational capabilities for drug discovery have grown significantly over the last decade, increasing the utilization of these techniques.
Major Players Profiled in the Market Report:
Segments
Increasing Use in Research to Propel Software Segment Growth
Based on offering, the market is divided into software and services. The software segment is expected to hold a prominent market share due to the increasing focus of drug design labs on conducting studies with molecular modelling software and significant advancements in the software itself.
High Applicability in Biomolecule Simulation to Drive Molecular Mechanics Segment Expansion
By approach, the market is subdivided into quantum mechanics, molecular mechanics, and others. The molecular mechanics segment is expected to hold a major market share due to its primary use in applications such as analyzing drug-macromolecule interactions and its suitability for simulating large biomolecules like proteins and nucleic acids.
Rising R&D Investments to Dominate Drug Development Application Segment
Based on application, the market is fragmented into drug discovery, drug development, and others. The drug development segment is expected to hold a significant market share, driven by rising R&D investments from biopharmaceutical companies to launch new medicines.